Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276728 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 182
- Enrollment target
NCT03276728 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 182 participants.
The verdict
NCT03276728, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 182 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
Interventions
- DRUG Placebo IV
- DRUG AMG 986 IV
- DRUG AMG 986 PO
- DRUG Placebo PO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2016-08-12 |
| Est. Completion | 2019-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03276728
The ClinicalTrials.gov registry entry for NCT03276728 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo IV is the first listed.
NCT03276728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03276728 about?
NCT03276728 is a clinical study titled "Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients". To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
What is the current status of trial NCT03276728?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 182 participants. The study started on 2016-08-12. Estimated completion is 2019-04-18.
What interventions are being tested in trial NCT03276728?
The interventions under investigation include: Placebo IV (DRUG), AMG 986 IV (DRUG), AMG 986 PO (DRUG), Placebo PO (DRUG).
Who is sponsoring clinical trial NCT03276728?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.